CJC-1295 DAC
CJC-1295 DAC is a long-acting GHRH analog that binds to albumin, ensuring sustained release of GH and IGF-1 over several days. It is highly useful in research into muscle growth, fat metabolism, anti-aging, and recovery.
$0.00
-
Official retailer
-
Quality guaranteed
-
Within 2 Days Delivery
-
99% Purified
CJC-1295 DAC (Drug Affinity Complex) is a long-acting analog of growth hormone-releasing hormone (GHRH) designed to increase growth hormone (GH) secretion and stimulate IGF-1 levels. Unlike its non-DAC counterpart, CJC-1295 DAC binds to albumin in the blood, significantly extending its half-life. This enables sustained GH release over a period of days, making it highly useful in research involving muscle growth, fat metabolism, anti-aging, and recovery processes.
– Form: Lyophilized peptide
– Purity: >99%
– Origin: Manufactured and tested in the USA
– Certifications: Certificate of Analysis (COA) included
CJC-1295 DAC works by:
– Binding to growth hormone-releasing hormone receptors
– Stimulating pulsatile growth hormone release from the anterior pituitary
– Enhancing IGF-1 production from the liver
– Binding to albumin via Drug Affinity Complex (DAC), extending its half-life to ~8 days
– Muscle growth and lean body mass studies
– Fat metabolism and lipolysis experiments
– Recovery and regenerative applications
– Aging and longevity models
– Endocrine and GH pathway investigation
– Long-acting GH stimulation via DAC
– Improved compliance and steady plasma levels
– Increased GH and IGF-1 without desensitization
– Synergistic potential with GHRPs and other growth-promoting peptides
Each vial is:
– Produced in a GMP-compliant U.S. facility
– Supplied with a Certificate of Analysis (COA)
– Tested via HPLC and mass spectrometry
– Shipped securely from the USA
– Contents: 2mg lyophilized CJC-1295 DAC peptide
– Appearance: White/off-white powder
– Solubility: Sterile bacteriostatic water recommended
– Storage: Store lyophilized powder at -20°C; stable up to 30 days post-reconstitution when refrigerated
*For laboratory research use only. Not intended for human or veterinary use.*
– Sold strictly for research purposes
– Not for human consumption or diagnostic use
– Researchers must adhere to applicable legal and institutional safety protocols
CJC-1295 DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) extends its half-life, making it ideal for research focused on sustained growth hormone (GH) release and its downstream effects on metabolism, tissue repair, and IGF-1 production.
CJC-1295 DAC binds to GHRH receptors in the anterior pituitary, stimulating a natural increase in GH secretion. Thanks to the DAC modification, the peptide binds to albumin in the blood, significantly extending its half-life to about 5–8 days. This provides a steady, prolonged GH elevation in lab models.
We provide CJC-1295 DAC as a lyophilized powder in sterile, single-use vials. It is synthesized and tested in the United States and packaged under strict quality control for reliable research applications.
Store lyophilized CJC-1295 DAC at -20°C, in a dry, light-protected environment. After reconstitution, keep the vial refrigerated at 2–8°C and use within your laboratory’s stability parameters.
Each batch is lab-verified to be ≥98% pure using HPLC and Mass Spectrometry. You’ll receive a full Certificate of Analysis (COA) with your order, confirming identity, purity, and quality.
Yes. Although CJC-1295 DAC is stable during standard shipping conditions, cold-chain shipping is available for sensitive orders or researchers who prefer temperature-controlled transit.
In research settings, CJC-1295 DAC is often studied in combination with other growth hormone secretagogues to evaluate synergistic effects. All usage must remain within approved laboratory research protocols.
Go to our Lab Test Results page, choose ‘CJC-1295 DAC’ from the product list, and submit your email address. We’ll send you the COA for your specific batch, providing complete transparency.
Shop Peptides Direct provides U.S.-made, ≥98% pure CJC-1295 DAC backed by lab testing, documentation, and fast fulfillment. We include a Certificate of Analysis with every order and offer a Price Match Guarantee—if you find the same grade for less, we’ll match it. Your research deserves no compromises.
CJC-1295 DAC (2 mg & 5 mg Vial) Dosage Protocol
Quickstart Highlights
CJC-1295 DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification binds reversibly to albumin, extending the peptide's half-life to approximately 6–8 days[1]. By stimulating pituitary GHRH receptors, CJC-1295 DAC increases GH secretion and circulating IGF-1 in a dose-dependent manner[2]. This educational protocol presents both once-weekly (2 mg) and twice-weekly (5 mg) subcutaneous approaches using practical dilutions for clear insulin-syringe measurements.
5 mg Vial (Twice Weekly)
- Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) concentration.
- Typical dose range: 300–1000 mcg per injection, twice weekly (gradual titration).
- Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.
2 mg Vial (Once Weekly)
- Reconstitute: Add 1.0 mL bacteriostatic water → 2.0 mg/mL (2,000 mcg/mL) concentration.
- Typical weekly dose: 2,000 mcg (2 mg) once weekly — the full vial per injection.
- Easy measuring: At 2.0 mg/mL, 1 unit = 0.01 mL = 20 mcg on a U-100 insulin syringe; full dose = 100 units (1.00 mL).
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing
Standard / Gradual Approach
5 mg Vial (2 mL = 2500 mcg/mL) - Twice Weekly
| Week | Per-Injection Dose (mcg) | Units (per injection) (mL) | Weekly Total |
|---|---|---|---|
| Weeks 1–2 | 300 mcg (0.3 mg) | 12 units (0.12 mL) | 600 mcg/week |
| Weeks 3–4 | 500 mcg (0.5 mg) | 20 units (0.20 mL) | 1000 mcg/week |
| Weeks 5–6 | 750 mcg (0.75 mg) | 30 units (0.30 mL) | 1500 mcg/week |
| Weeks 7–12 | 1000 mcg (1 mg) | 40 units (0.40 mL) | 2000 mcg/week |
Frequency: Inject twice weekly subcutaneously (e.g., Monday/Thursday or Tuesday/Friday). The extended 6–8-day half-life from the DAC modification supports less frequent dosing compared to non-DAC GHRH analogs[1][2].
2 mg Vial (1 mL = 2.0 mg/mL) - Once Weekly
| Week | Weekly Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–12 | 2,000 mcg (2 mg) | 100 units (1.00 mL) |
Frequency: Inject once weekly subcutaneously, preferably in the evening before bed to align with natural nocturnal GH surges[6]. The peptide's extended half-life (~6–8 days) supports weekly administration without significant loss of activity between doses[1].
For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw the appropriate volume of bacteriostatic water (1.0 mL for 2 mg vial, 2.0 mL for 5 mg vial) with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on an 8–16 week protocol with appropriate frequency.
5 mg Vials (Twice Weekly)
- 8 weeks ≈ 3 vials (~10.2 mg total)
- 12 weeks ≈ 4 vials (~18.2 mg total)
- 16 weeks ≈ 6 vials (~26.2 mg total)
2 mg Vials (Once Weekly)
- 8 weeks: 8 vials (1 vial/week)
- 12 weeks: 12 vials (1 vial/week)
Insulin Syringes (U-100)
- Twice Weekly: 2 syringes/week → 8 weeks: 16 syringes, 12 weeks: 24 syringes, 16 weeks: 32 syringes
- Once Weekly: 1 syringe/week → 8 weeks: 8 syringes, 12 weeks: 12 syringes
Bacteriostatic Water (10 mL bottles)
Use 1.0 mL per 2 mg vial or 2.0 mL per 5 mg vial for reconstitution.
- 5 mg protocol (8 weeks, 3 vials): 6 mL → 1 × 10 mL bottle
- 2 mg protocol (8 weeks, 8 vials): 8 mL → 1 × 10 mL bottle
- 2 mg protocol (12 weeks, 12 vials): 12 mL → 2 × 10 mL bottles
Alcohol Swabs
One for the vial stopper + one for the injection site each injection.
- Twice Weekly: 4 swabs/week → 8 weeks: 32 swabs
- Once Weekly: 2 swabs/week → 8 weeks: 16 swabs
Protocol Overview
Concise summary of the regimens.
- Goal: Support sustained GH and IGF-1 elevation for research into GH-axis effects[1].
- Schedule: 2 mg: Once weekly for 8–12 weeks; 5 mg: Twice weekly for 8–12 weeks.
- Dose Range: 2 mg: 2000 mcg weekly; 5 mg: 300–1000 mcg per injection with gradual titration.
- Reconstitution: 1.0 mL per 2 mg vial (2.0 mg/mL) or 2.0 mL per 5 mg vial (2.5 mg/mL) for accurate measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested administration approaches.
- 2 mg Vial: 2000 mcg once weekly[7]; Conservative: 1000 mcg weekly.
- 5 mg Vial: Start 300 mcg twice weekly; increase by ~250 mcg every 2 weeks as tolerated.
- Target: 5 mg: 750–1000 mcg per injection by Weeks 5–12.
- Frequency: 2 mg: Once weekly; 5 mg: Twice weekly, spaced 3–4 days apart.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for 2–4 weeks; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document each dose, injection site, and timing to maintain consistency.
- The DAC modification provides sustained release; maintain consistent scheduling.
- The 5 mg vial provides more doses per vial, reducing reconstitution frequency.
How This Works
CJC-1295 DAC is a modified 30-amino-acid GHRH analog conjugated to a Drug Affinity Complex (DAC) that covalently binds to serum albumin after injection[1]. This albumin binding dramatically extends the peptide's half-life from minutes to approximately 6–8 days, enabling once-weekly or twice-weekly dosing[2]. CJC-1295 mimics endogenous GHRH, binding to GHRH receptors on pituitary somatotrophs to drive GH release[2]. The resulting GH surge stimulates IGF-1 production (primarily in the liver); IGF-1 then mediates many growth and metabolic effects through JAK/STAT signaling pathways[4]. Notably, pulsatile GH secretion persists even during continuous CJC-1295 stimulation, preserving physiological release patterns[2].
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- Supports sustained elevation of GH and IGF-1 in a dose-dependent manner[1].
- May promote increased lean body mass, reduced fat mass, and improved body composition consistent with GH/IGF-1 axis activation[4][9].
- Enhanced protein synthesis and recovery potential through anabolic signaling[4].
- Improved sleep quality — GHRH analogs may have somnogenic effects, increasing deep slow-wave sleep[6].
- Preserves natural GH pulsatility unlike exogenous GH administration[11].
- Generally well tolerated; occasional mild injection-site reactions, transient flushing, headache, or water retention may occur[1][7].
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, protein-forward diet tailored to energy and recovery needs.
- Combine resistance training and aerobic activity to reinforce GH-mediated adaptations.
- Prioritize quality sleep (7–9 hours) as endogenous GH release peaks during deep sleep[4][6].
- Manage stress to support hormonal balance and adherence.
- Avoid eating 2+ hours before injection to optimize GH release response.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[5][6][9][10].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[5][8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[5].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[6][7].
- Do not rub or massage the injection site after administration[8].
- Immediately dispose of the used syringe in a proper sharps container[9].
Recommended Source
We recommend Shop Peptides Direct for high-purity CJC-1295 DAC (2 mg & 5 mg).
Why Shop Peptides Direct?
- High-purity, third-party-tested lots with batch COAs.
- Consistent, ISO-aligned handling and documentation.
- Reliable fulfillment to maintain cold-chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
-
J Clin Endocrinol Metab (2006) — Teichman SL et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults
-
J Clin Endocrinol Metab (2006) — Ionescu M et al. Pulsatile GH secretion persists during continuous CJC-1295 stimulation
-
Clinical Pharmacology & Therapeutics — DAC technology: albumin-binding for extended peptide half-life
-
StatPearls (NCBI Bookshelf) — Brinkman JE et al. Physiology, Growth Hormone
-
CDC Pink Book (Chapter 6) — Vaccine administration: subcutaneous route (angle/site; no aspiration)
-
PubMed — Physiology of growth hormone secretion during sleep
-
Journal of Clinical Endocrinology & Metabolism — Safety and tolerability of CJC-1295 at various dose levels in healthy subjects
-
Immunize Canada — How to Vaccinate: Best Practices (subcutaneous injection technique)
-
Postgrad Med J (2006) — Ayuk J, Sheppard MC. Growth hormone and its disorders
RELATED PRODUCTS
Ipamorelin
Reviews
There are no reviews yet.